ProCE Banner Activity

What to Know About the Novel Anti–LAG-3 Checkpoint Inhibitor Relatlimab in Melanoma

Clinical Thought
In this commentary, Dr. Evan Lipson reviews LAG-3 as a therapeutic target and discusses evidence from the RELATIVITY-047 trial of the combination of the anti–LAG-3 antibody relatlimab plus nivolumab as first-line therapy in advanced melanoma.

Released: March 21, 2022

Expiration: March 20, 2023

Share

Faculty

Evan J. Lipson

Evan J. Lipson, MD

Associate Professor of Oncology
Melanoma and Cancer Immunology Programs
Bloomberg-Kimmel Institute for Cancer Immunotherapy
Johns Hopkins University School of Medicine
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Bristol Myers Squibb

Faculty Disclosure

Primary Author

Evan J. Lipson, MD

Associate Professor of Oncology
Melanoma and Cancer Immunology Programs
Bloomberg-Kimmel Institute for Cancer Immunotherapy
Johns Hopkins University School of Medicine
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Evan J. Lipson, MD, has received consulting fees from Array BioPharma, Bristol-Myers Squibb, EMD Serono, Genentech, MacroGenics, Merck, Novartis, Odonate Therapeutics, Regeneron, and Sanofi and funds for research support paid to his institution from Bristol-Myers Squibb, Merck, Regeneron, and Sanofi.